HK1219690A1 - 利用抗生素來治療超重和肥胖患者感染的方法 - Google Patents

利用抗生素來治療超重和肥胖患者感染的方法

Info

Publication number
HK1219690A1
HK1219690A1 HK16107660.6A HK16107660A HK1219690A1 HK 1219690 A1 HK1219690 A1 HK 1219690A1 HK 16107660 A HK16107660 A HK 16107660A HK 1219690 A1 HK1219690 A1 HK 1219690A1
Authority
HK
Hong Kong
Prior art keywords
overweight
antibiotics
methods
obese patients
treating infections
Prior art date
Application number
HK16107660.6A
Other languages
English (en)
Inventor
M Duffy Erin
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51581190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1219690(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of HK1219690A1 publication Critical patent/HK1219690A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK16107660.6A 2013-03-15 2016-06-30 利用抗生素來治療超重和肥胖患者感染的方法 HK1219690A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790179P 2013-03-15 2013-03-15
PCT/US2014/027220 WO2014152332A1 (en) 2013-03-15 2014-03-14 Methods of treating infections in overweight and obese patients using antibiotics

Publications (1)

Publication Number Publication Date
HK1219690A1 true HK1219690A1 (zh) 2017-04-13

Family

ID=51581190

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16107660.6A HK1219690A1 (zh) 2013-03-15 2016-06-30 利用抗生素來治療超重和肥胖患者感染的方法

Country Status (14)

Country Link
US (3) US20160058750A1 (zh)
EP (1) EP2969004A4 (zh)
JP (2) JP6617097B2 (zh)
KR (1) KR102237887B1 (zh)
AR (1) AR095594A1 (zh)
AU (2) AU2014239965A1 (zh)
BR (1) BR112015023044A8 (zh)
CA (1) CA2904387C (zh)
CL (1) CL2015002759A1 (zh)
HK (1) HK1219690A1 (zh)
IL (1) IL241113A0 (zh)
MX (1) MX2015011760A (zh)
TW (1) TWI641372B (zh)
WO (1) WO2014152332A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201605447A (zh) * 2014-06-20 2016-02-16 美林塔治療學有限公司 處理感染的方法
US20160243190A1 (en) 2015-02-23 2016-08-25 Theravance Biopharma Antibiotics Ip, Llc Doses and methods for administering telavancin
CN107216353B (zh) * 2016-03-21 2020-05-19 山东诚创医药技术开发有限公司 一种头孢洛林酯咪唑盐的精制方法
SG11201811345TA (en) 2016-07-14 2019-01-30 Achaogen Inc Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010056872A2 (en) * 2008-11-15 2010-05-20 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions

Also Published As

Publication number Publication date
EP2969004A4 (en) 2016-09-21
US20160058750A1 (en) 2016-03-03
BR112015023044A8 (pt) 2021-09-28
KR102237887B1 (ko) 2021-04-07
US20240165100A1 (en) 2024-05-23
TWI641372B (zh) 2018-11-21
CA2904387C (en) 2021-12-07
AU2019200483A1 (en) 2019-02-14
AU2014239965A1 (en) 2015-09-24
JP2019196401A (ja) 2019-11-14
KR20150133762A (ko) 2015-11-30
JP2016513689A (ja) 2016-05-16
EP2969004A1 (en) 2016-01-20
CA2904387A1 (en) 2014-09-25
MX2015011760A (es) 2016-06-10
BR112015023044A2 (pt) 2017-07-18
TW201513862A (zh) 2015-04-16
CL2015002759A1 (es) 2016-04-22
JP6617097B2 (ja) 2019-12-04
WO2014152332A1 (en) 2014-09-25
AR095594A1 (es) 2015-10-28
US20220257584A1 (en) 2022-08-18
IL241113A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
HK1216251A1 (zh) 吡唑並吡咯烷衍生物及其治病作用
PL3010521T3 (pl) Kompozycje synbiotyczne do leczenia zakażeń u pacjentów alergicznych
EP2981611A4 (en) ANTIBIOTICUM PROTOCOLS AND PHARMACEUTICAL FORMULATIONS AND TREATMENT METHODS THEREWITH
SG11201602070TA (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
HK1221178A1 (zh) 卡博替尼劑型及其在癌症治療中的使用
HK1217289A1 (zh) 使用細菌治療癌症的組合物和方法
GB201320723D0 (en) Composition and methods of treatment
HK1222398A1 (zh) 治療伯克霍爾德氏菌感染症的組合物及方法
PT3004108T (pt) Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
IL242770B (en) A therapeutic combination that includes oxazolidinone-quinolones for use in the treatment of bacterial infections
HK1218537A1 (zh) 香豆素衍生物以及用於治療過度增生性疾病的方法
HRP20190219T1 (hr) Spojevi za tretman pretilosti i postupci za njihovu uporabu
HK1219690A1 (zh) 利用抗生素來治療超重和肥胖患者感染的方法
HK1208159A1 (zh) 在治療肥胖症及超重中的應用
GB201410954D0 (en) Skin treatment devices and methods
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
PT3052476T (pt) Inibidores de nicotinimida substituídos de btk e sua preparação e uso no tratamento do cancro, inflamações e doenças autoimunes
TH1401007652A (th) อะมิโนไตรอะโซโลไพริดีนสำหรับการใช้ในการรักษาการอักเสบ และองค์ประกอบทางเภสัชกรรมของมัน
GB201301685D0 (en) Diagnosis and treatment of cancer